Pleasanton, Calif., June 30, 2021—Apton Biosystems, Inc., a developer of Super-Res sequencing and single-molecule detection systems for large-scale clinical applications, such as early cancer detection and population sequencing, today announced the close of a $24 million Series-A financing. The financing was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures. Concurrent with the financing, Jay Kern of Kern Capital has joined Apton’s board of directors.
Press Releases
Pleasanton, Calif., May 01, 2021—Apton Biosystems, Inc., a developer of Super-Res™ sequencing instruments for large-scale clinical applications such as early cancer detection and population sequencing, today announced the appointment of John W. Hanna as chief executive officer and board director.
Mr. Hanna has more than 20 years of senior healthcare management experience, including ten years at genomic diagnostics company Veracyte, Inc., where his roles included chief commercial officer and vice president of marketing. Prior to that, Mr. Hanna held sales and business development roles at IBM, Humana, Inc, and America’s Health Insurance Plans (AHIP).
